Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab

Pediatric Pulmonology

Volumn 47, Issue 1, 2012, Pages 84-87

  Popler, Jonathan ^a   Alimohammadi, Mohammad ^b   Kämpe, Olle ^b   Dalin, Frida ^b   Dishop, Megan K ^c   Barker, Jennifer M ^d   Moriarty Kelsey, Margaret ^d   Soep, Jennifer B ^d   Deterding, Robin R ^d  

^a Georgia Pediatric Pulmonology Associates PC   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF COLORADO   (United States)

^d University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

AIRE gene; Autoimmune Polyendocrine Syndrome Type 1; Autoimmune Polyendocrinopathy Candidiasis and Ectodermal Dysplasia; KCNRG Autoantibodies; Rituximab

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; MYCOPHENOLIC ACID; POTASSIUM CHANNEL REGULATORY PROTEIN AUTOANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; BRONCHIECTASIS; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG DISEASE; MALE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES; MALE; POLYENDOCRINOPATHIES, AUTOIMMUNE; POTASSIUM CHANNELS; SYNDROME;

EID: 84155167273     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21520     Document Type: Article

References (15)

1. Husebye ES, Perheentupa J, Rautemaa R, Kämpe O,. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009; 265: 514-529.
2. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J,. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829-1836. (Pubitemid 20200407)
3. De Luca F, Valenzise M, Alaggio R, Arrigo T, Crisafulli G, Salzano G, Cervato S, Mariniello B, Lazzarotto F, Betterle C,. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. Eur J Pediatr 2008; 167: 1283-1288.
4. Alimohammadi M, Dubois N, Sköldberg F, Hallgren A, Tardivel I, Hedstrand H, Haavik J, Husebye ES, Gustafsson J, Rorsman F, Meloni A, Janson C, Vialettes B, Kajosaari M, Egner W, Sargur R, Pontén F, Amoura Z, Grimfeld A, De Luca F, Betterle C, Perheentupa J, Kämpe O, Carel JC,. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc Natl Acad Sci USA 2009; 106: 4396-4401.
5. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF,. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-1580.
6. Kim JH, Kim YH, Kim MR, Kim SC,. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 1365-2133.
7. Burusnukul P, Brennan TD, Cupler EJ,. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase+myasthenia gravis. J Clin Neuromuscul Dis 2010; 12: 85-87.
8. Gavanescu I, Benoist C, Mathis D,. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. Proc Natl Acad Sci USA 2008; 105: 13009-13014.
9. Liossis SN, Sfikakis PP,. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008; 127: 280-285.
10. Alimohammadi M, Björklund P, Hallgren A, Pöntynen N, Szinnai G, Shikama N, Keller MP, Ekwall O, Kinkel SA, Husebye ES, Gustafsson J, Rorsman F, Peltonen L, Betterle C, Perheentupa J, Akerström G, Westin G, Scott HS, Holländer GA, Kämpe O,. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008; 358: 1018-1028. (Pubitemid 351347101)
11. Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N,. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006; 3: e289.
12. Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A,. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207: 299-308 [Epub 2010].
13. Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL,. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr Opin Immunol 2010; 22: 467-474 [Epub 2010 Jul 30. Review].
14. Ahlgren KM, Moretti S, Lundgren BA, Karlsson I, Ahlin E, Norling A, Hallgren A, Perheentupa J, Gustafsson J, Rorsman F, Crewther PE, Rönnelid J, Bensing S, Scott HS, Kämpe O, Romani L, Lobell A,. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model. Eur J Immunol 2011; 41: 235-245. DOI: 10.1002/eji.200939883 [Epub 2010 Dec 3].
15. Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O'Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS,. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci Transl Med 2009; 1: 9ra20.